Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When is the next Q or K due? Will be interested to take a look at the current financials and Management Comments.
Whatever they put in the test equipment/modulator is not commercially viable is my read on the PR.
From the quote below, it sounds like they need to first create a variant of the material they used in the record setting demo. This variant that they hope to bring to market may not yet exist either, or is not yet developed enough to validate in meeting all necessary commercial testing requirements (simple/cheap to manufacture, simple to integrate with fabs, meets temperature stability specs, etc).
"NLM expects to commercialize a variant of BAH13 that is a crosslinkable, heat-resistant material, like HLD, for on-chip use. "
If their technology looks to be viable, perhaps we will buy them once our partnerships become official and our sales start coming in as we seem MUCH closer to market.
Assuming that means we should be due for a reversal to an upward trend?
Hi SteveSchiets - noted your mentioning this company over on the LWLG board. Any place you might recommend starting as far as best overview of where the company is at and their potential? Are there any investor presentations available like those that Lebby gives?
I've reviewed the following:
https://www.spectra7.com/Spectra7CompanyOverview11-29-2021.pdf
Are you expecting similar potential as with LWLG?
Thanks in advance!
Funny, I was wondering the same thing and asked LWLG/MZ Group. They responded that as a matter of policy they do not comment on other companies' technology. Understandable - oh well.
This makes me chuckle too and perhaps someone should update the WIKI for EO modulators, as ours can operate at sub 1 volt levels. It would seem the tables have turned regarding the statement below:
"Compared with an Electro-optic modulator (EOM), an EAM can operate with much lower voltages (a few volts instead of ten volts or more)."
Wow, interesting indeed Steve! Seems like something we'd want to be involved with if we aren't.
"The new platform co-integrates III-V lasers, semiconductor optical amplifiers (SOA), electro-absorption modulators (EAM) and photodetectors with silicon photonics devices, all monolithically on a single chip. This enables smaller, higher-channel count and more power-efficient optical architectures and solutions. Foundry availability will enable a broad array of product developers to create highly integrated photonic integrated circuits (PICs) for diverse markets.
Process design kits (PDK) are expected to be available by year end and the first open multi-project wafer (MPW) run are expected to be offered early next year. First samples of full 400Gb/s and 800Gb/s PICs reference designs with integrated laser are expected to be available in the second quarter of 2022.
“Our mutual development work with Tower has been extraordinarily successful in qualifying this innovative silicon photonics technology in a high-volume manufacturing facility,” said Rami Rahim, CEO of Juniper Networks. “By offering this capability to the entire industry, Juniper offers the potential to radically reduce the cost of optics while lowering the barrier to entry for customers”."
Indeed - it would seem they've had some fairly successful investor conferences of late!
Regarding foundry partnerships it sounds like it's just a matter of when, not if, at this point. I don't think he'd harp on "Ubiquitous" if that were not the case. Hoping we get our first official foundry partner by end of January - things certainly sound like they are very close!
New presentation tomorrow! Wonder if we'll get any new info :)
Oppenheimer's 5G Summit: Wireless and Cloud Convergence
Date: Tuesday, December 14, 2021
Time: 10:45 a.m. Eastern time (7:45 a.m. Pacific time) - Track 3
Webcast: https://wsw.com/webcast/oppenheimer19/lwlg/2799300
I suppose this tweet may attract some shorts?
After the run up in SP this week, will be looking forward to a new Lebby presentation next week!
Oppenheimer's 5G Summit: Wireless and Cloud Convergence
Date: Tuesday, December 14, 2021
Time: 10:45 a.m. Eastern time (7:45 a.m. Pacific time) - Track 3
Webcast: https://wsw.com/webcast/oppenheimer19/lwlg/2799300
Seems reasonable. After all, going from $20 - $30/share is ONLY a 50% rise
Investor conferences both this week and next...would be a GREAT time to release any positive new developments.
From the November 16th PR:
"Looking ahead to the final quarter of 2021 and into 2022, we continue to work closely with our partners under NDA - which include semiconductor foundries - to enhance our commercial positioning through ongoing innovation. I look forward to providing further updates in the near-term as we strive to create sustainable, long-term value for our shareholders," concluded Dr. Lebby.
Preferred shares getting cashed out?
New presentation on the LWLG website, not sure if this has been discussed?:
5th PIC International Conference Keynote Presentation
https://www.lightwavelogic.com/presentation/5th-pic-international-conference-keynote-presentation/
Ooof, above mine as well. I'm sure if someone heard anything they'd report it anyway, this board is fantastic - not sure why I bothered to ask!
Did anyone watch? Or is the presentation later in the day?
That's true, I imagine they will have at least partial payment due upon results and would want to replenish their funds now in advance of risky trial results.
Forgive my ignorance, but presumably the $2 million proceeds from the sale of the preferred shares goes to the company. What could they be needing an extra $2 mil for at this time? The B-IBD/UC drug reformulation? Settle liabilities?
Anyone care to venture a guess on the following scenarios:
1) Share price after great results (primary endpoint met) - ???
2) Share price after good results (primary endpoint not met but substantial improvement in various populations or measures of benefit - ???
3) Share price after "ok" results (primary endpoint not met and some minimal positive impacts recognized) - ???
I'd include the share price after poor results but we all know that would tank the stock, no need to venture a guess there.
Perhaps locking in profits for EOY
Currently, there is nothing approved for moderate to severe cases of COVID19, correct? So if approved, we'd be the only game in town at the moment? I'd think the barrier to approval would be significantly less stringent for this population. Hopefully good results and a speedy EUA on our horizon...
If successful and approved for COVID, and the Bio lab / Government lab testing continues to show success against other viruses, I'd imagine it will be much easier for analysts and Institutional buyers to see the potential value here, especially with a large pharma partner running multiple trials per your example. A $5B market cap (~$10/share) should be feasible relatively quickly in this scenario IMO.
So, how would IPIX pivot to a Phase 2/3 registration enabling trial as a broad spectrum anti-viral for multiple classes of moderate to severe virus cases (influenza, coronavirus, enveloped, non-enveloped etc) requiring hospitalization?
Would we need to design a Phase 3 for each separate class of virus separately or would there be a way to combine a number of them together? Thoughts? I'd think this is where a deep pocketed partner would come into play as they could surely see the massive potential for success and $$$
From the S-1 Amendment at the end of August 2021:
Plan of Operations
During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:
We plan to develop a line of fabrics and apparel under the SpydaSilk Entprises joint venture with Kings Group, creating a line of fashion wear under the Company Spydasilk Enterprises Pte. Ltd with trade names including SpydasilkTM, SpydraTM, and others.
We plan to accelerate both our microbiology and selective breeding programs as well as provide more resources for our material testing protocols. We spent approximately $209,000 over the last 6 months on research and development of high strength polymers. In the first half of 2021, we directed our research and development efforts on growing our internal capabilities; we plan to continue to dedicate our efforts in the balance of 2021 and 2022 to grow our internal research and development programs.
We plan to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile and other industries.
We plan to continue the expansion of our production operations at our Quang Nam, Vietnam factory in accordance with our investment and enterprise registration certificates, including the planting of additional mulberry fields in collaboration with local farming cooperatives and the hiring of additional direct staff for our factory as needed.
We will consider buying an established revenue producing company in a compatible business, in order to broaden our financial base and facilitate the commercialization of our products; as of the date hereof, we have not had any formal discussion or entered into any definitive agreements regarding any such purchase.
We will also actively consider pursuing collaborative research opportunities with both private and university laboratories in areas of research which overlap the company’s existing research and development. One such potential area for collaborative research which the company is considering is protein expression platforms. If our financing allows, management will give strong consideration to increasing the breadth of our research to include protein expression platform technologies.
We plan to actively pursue collaborative research and product testing opportunities with companies in the biotechnology, materials, textile and other industries.
We plan to actively pursue collaborative commercialization, marketing and manufacturing opportunities with companies in the textile and material sectors for the fibers we developed and for any new polymers that we create in the remainder of 2021 and going forward.
We plan to actively pursue the development of commercial scale production of our recombinant materials including Monster Silk®, Dragon SilkTM, SpydasilkTM, and SpydraTM.
We have initiated and plan to accelerate our efforts for large scale U.S. production. This work will include the research and production of a new transgenic tailored specifically domestic production
I saw TSMC and GF listed. TSMC was a very small icon at the bottom of the page. I didn't look for Samsung specifically, however.
I imagine this is just a generic list of foundries, not truly specific to who they are or aren't working with.
Next week is the start of "mid" October...it's been a long road but we are closing in on trial results here.
This makes the most sense to me as well.
Opportunities knock and if we take too long, other potential customers/clients/partners will go it alone or find alternate solutions to their issues. They can't sit back and wait while we grow organically before we have the capacity and bandwidth to work together. Demand for our time, services, and products is likely competitive and outpaces our supply so to speak. We need to spend some money if we're going to make the most of these growth opportunities.
Got it and thanks for clarifying. As Lemoncat also indicated, those on ventilators / assisted breathing machines at the time of randomization are excluded from the study. Phew!
That's a HUGE relief! Thanks for clarifying.
I agree, it shouldn't. However, the way the primary endpoint is defined/written, it sounds like we may be on the hook regardless for the success of that endpoint. For better or worse, sometimes just the way a protocol is written can affect the way the outcome gets reported and is perceived. That's why top clinical operations talent is imperative. I am anxiously looking forward to the results in a few weeks time and hoping for the best - this just seems like a potential oversight that could have broader implications for the market reaction (and path forward) with whatever the results end up showing.
Primary Outcome Measures :
Time to sustained recovery through Day 29 [ Time Frame: Day 1 through Day 29 ]
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale with response sustained through Day 29:
-Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than for per protocol dosing or assessments, as appropriate);
-Not hospitalized, limitation on activities and/or requiring home oxygen;
-Not hospitalized, no limitations on activities.
Based on the Primary Outcome Defined in the Trial, it would seem that continuing to require supplemental oxygen would count against us? Presumably that would include a ventilator.
I'm wondering if the trial design for the Primary Outcome could have been made better to highlight the positive actions of Brilacidin more on the anti-viral and anti-inflammatory end of things rather than just a Primary measure for "the patient is all better now or isn't".
I may be mistaken, but even if the patient recovers from just the COVID virus itself very successfully with substantially less inflammation, any damage to the body that the virus has done prior to treatment remains and Brilacidin was never designed or intended as a regenerative medicine to restore function to damaged lungs (or other organs) - it was only designed to be an antiviral and antibacterial and anti-inflammatory. Again, unless I am mistaken, which I hope to be, it seems we might be evaluated unfairly in that regard but I hope they are able to elucidate this in the results and clearly show benefit where you would expect it based on what the drug is designed to do.
OT: Is there an investment presentation?
Perhaps its a bit of a translation issue and they just mean that the product is available for purchase right now and not just an R&D project?
Hopefully it just means what it sounds like!!!
Thanks - 40 business days or continuous?
I'll assume it has already been posted there, but this might be a good addition to the Reddit board for that blogger/author that had questions on their technology.
Excellent - mind posting a link to the Reddit thread in question? Or sending a PM to me with that if you're able? I'll be curious to see the reaction.
Good to know that he is "objective" and can be corrected, speaks to a purer intention for fact finding.
Based on his questions, it sounds like perhaps he doesn't realize or understand that we aren't necessarily a competing technology, but additive, enabling and complementary when integrated with existing Silicon Photonic solutions such as that of Intel etc.
Understandably, the knee jerk reaction from someone new to this company would be to view us solely as a competitor and not a partner to enhance your existing technology suite. We are solely a competitor to an Intel, Broadcom, Cisco etc only in the event that they don't incorporate our technology into theirs.